Skip to main content
Hualan Biological Engineering Inc. logo

Hualan Biological Engineering Inc. — Investor Relations & Filings

Ticker · 002007 ISIN · CNE000001JN8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,526 across all filing types
Latest filing 2016-12-23 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002007

About Hualan Biological Engineering Inc.

https://www.hualanbio.com

Hualan Biological Engineering Inc. is a biopharmaceutical enterprise specializing in the research, development, production, and commercialization of blood products and vaccines. The company’s portfolio is divided into two primary segments: plasma-derived therapeutics and viral vaccines. Key blood products include human albumin, intravenous immunoglobulin (IVIG), human coagulation factor VIII, and prothrombin complex. In the vaccine sector, the company produces seasonal influenza vaccines, including quadrivalent formulations, as well as hepatitis B and rabies vaccines. Hualan Biological Engineering operates advanced manufacturing facilities and plasma collection centers, focusing on high-quality standards and technological innovation in recombinant protein drugs and monoclonal antibodies to address critical medical needs in immunology, hematology, and infectious disease prevention.

Recent filings

Filing Released Lang Actions
关于血液制品新建分装线通过GMP认证的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from a company about receiving GMP certification for a new production line, including details about the certification and its impact on future performance. It is not a financial report, earnings release, or management discussion. It is an official company announcement related to regulatory certification and operational update, not fitting into categories like Annual Report, Earnings Release, or Management Reports. It is also not a report publication announcement or a certification letter. Given the nature and length, it best fits under Regulatory Filings (RNS), which is the fallback for miscellaneous official announcements that do not fit other categories.
2016-12-23 Chinese
关于参股公司取得利妥昔单抗临床试验批件的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (756 characters) from a company about its associate company obtaining a clinical trial approval for a drug. It contains no financial data, no report or financial statements, and no mention of shareholder votes or management changes. It is an official announcement regarding regulatory approval related to clinical trials, which is a regulatory update but not a financial report or earnings release. The document is not a report itself but an announcement of a regulatory event. Given the content and length, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2016-12-12 Chinese
2016年第三季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2016 Third Quarter Report" of 华兰生物工程股份有限公司, indicating it is a quarterly financial report. It contains detailed financial data such as total assets, net profit, earnings per share, cash flow, and shareholder information for the third quarter of 2016. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year confirms it is an Interim / Quarterly Report. The document length (8168 characters) and content show it is the actual report, not just an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). 9M 2016
2016-10-26 Chinese
2016年第三季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2016 Third Quarter Report" of 华兰生物工程股份有限公司, indicating it is a quarterly financial report. It contains detailed financial data such as balance sheets, profit and loss statements, cash flow information, shareholder data, and management commentary on financial performance for the third quarter of 2016. The length of the document (15,000 characters) and the presence of substantive financial statements and analysis confirm it is a full interim/quarterly report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). 9M 2016
2016-10-26 Chinese
关于公司控股子公司对外捐赠的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement regarding a donation made by a company's subsidiary. It does not contain financial statements, management discussion, or detailed financial data. It is an announcement of a corporate action (donation) rather than a report or regulatory filing. The length is only 529 characters, indicating it is a brief notice. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is not related to board changes, voting results, or capital changes. The best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other categories.
2016-10-24 Chinese
关于全资子公司取得人凝血因子Ⅷ临床试验批件的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company about its wholly-owned subsidiary obtaining clinical trial approval for a pharmaceutical product. It includes risk warnings and regulatory information but does not contain financial data, management changes, voting results, or detailed financial reports. The document is short (730 characters) and serves as an update on regulatory approval status rather than a financial or management report. It fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2016-10-11 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.